A lesão pulmonar é a principal causa de morte da Esclerose Sistêmica (ES), e as alterações principais são: o acometimento intersticial e o vascular. No presente estudo analisamos através do microscópio confocal a laser 40 artérias pulmonares de pequeno e médio calibre de pacientes com ES e 16 controles. Medimos a área do lúmen, a área total do vaso e fizemos a subtração da área total do vaso menos a do lúmen, e a porcentagem da área do lúmen em relação à área total do vaso. Observou-se que a área do lúmen e a porcentagem da área do lúmen em relação a área total do vaso são significativamente menores na ES em relação ao controle, e que a diferença entre a área total do vaso e a área do lúmen foi maior no grupo ES. Os achados confirmaram a hipótese inicial de acometimento das artérias pulmonares na ES, que se encontram espessadas devido à inflamação, infiltração celular em suas camadas e ativação endotelial / Lung injury is the leading cause of death in Systemic Sclerosis (SSc), and the main changes are: the vascular and interstitial involvement. In this study we analyzed through the confocal laser microscope 40 lung arteries of small and medium-sized of patients with SSc and 16 arteries of control group. We measured the lumen area, the total vessel area, made the subtracting the total vessel area minus the lumen area and the percentage between the lumen area and total vessel area. It was observed that the lumen area and the percentage between the lumen area and total vessel area were significantly lower in SSc group compared to control group, and the difference between the total vessel and the lumen area was higher in SSc. The findings confirmed the initial hypothesis of pulmonary arterial injury in SSc, wich are thickened due to inflammation, cellular infiltration into its layers and endothelial activation

Uncontrolled growth of vascular stem cells as a result of endothelial-mesenchymal transition is considered to cause hyper-proliferative vascular remodeling in severe pulmonary arterial hypertension (PAH) patients. Hyperplastic intimal growth is one of the causes of closure of the lumen of pulmonary arterioles. This abnormal vessel remodeling leads to the progressive increase in pressure of the pulmonary arterioles causing severe PAH; and debilitating harm to patients resulting in mortality from right heart failure. Environmental factors, including polychlorinated biphenyls (PCBs), are considered to be involved in hyper-proliferative vascular remodeling because genetic makeup can only explain about 10% of severe PAH cases. PCB involvement in lung toxicity has received attention because (i) they have been reported to accumulate in the lung; (ii) PCBs produce pathological vascular remodeling in the experimental model; high levels of PCBs are found in human lung tissue; and (iii) epidemiological studies show the association between lung toxicity and PCBs; and prevalence of hypertension and elevated concentrations of particularly PCB153. Recent studies identify PCB153 as one of the largest contributors for total PCB body burden in humans. Our previous studies demonstrated PCB153 mediated vascular endothelial dysfunction and activated the inhibitor of differentiation protein 3 (ID3). ID3 is an important determinant of mitogen and reactive oxygen species-induced G1→S phase cell cycle progression. Although phosphorylation of ID3 increases cell growth by antagonizing the transcription of cell cycle inhibitors, still there is a critical gap in understanding the molecular mechanism(s) of pulmonary proliferative vascular remodeling associated with PCB exposure in humans and the role of the transcription regulator ID3. Our overall objective was to investigate ID3 mediated transcriptional reprogramming as a driver of PCB153-induced pathological proliferative vascular remodeling. Stable ectopic expression of ID3 in lung endothelial cells contributed to endothelial-mesenchymal transition (EndMT), cell proliferation, and cell migration. Using an endothelial spheroid assay, an established method to measure aberrant hyper-proliferation of endothelial cells in PAH patients, we show that stable ectopic expression of ID3 increased the number and size of vascular spheres. ID3 overexpressing cells exposed to environmentally relevant concentrations of PCB153 showed a two-fold increase in cell proliferation as determined by MTT, SRB, and BrdU assays. ID3 overexpressing cells showed the loss of VE-cadherin and gain of MMP9 and vimentin, which are markers of EndMT. PCB153 also increased phosphorylation of ID3 in lung endothelial cells. To determine the molecular mechanism by which ID3 contributes to hyper-proliferative endothelial cells, we investigated ID3 transcriptional reprogramming using ChIP-Seq and RNA-Seq technology. We show here for the first time that ID3 is part of a more general mechanism of transcriptional regulation. Our ChIP-Seq data show that ID3 binds to a subset of approximately 1200 target genes. Comprehensive motif analysis of ChIP-Seq data using the MEME Suite software toolkit revealed that ID3 bound to the GAGAGAGAGA motif sequence on genomic DNA. We also show a significant preference of ID3 binding to motifs associated with transcription factors IRF1, BC11A, IRF4, PRDM1, FOXJ3, SMAD4, ZBTB6, GATA1, and STAT2. Using an integrative approach of ChIP-Seq and RNA-Seq data, we identified 19 genes whose promoter region was bound by ID3 and RNA was differentially expressed in ID3 overexpressing cells. In summary, our data demonstrated that PCB153 and/or ID3 induces proliferation of lung endothelial cells via transcriptional reprogramming. Discoveries from these findings will lay the necessary groundbreaking work for testing the efficacy of ID3 antagonists for the prevention and treatment of pathological vascular remodeling as well as provide a new paradigm by which PCBs may contribute to lung vascular toxicity.

Pulmonary arterial hypertension (PAH) is a rare but fatal disease with an annual mortality rate of 15% despite current therapies. Uncontrolled proliferation of pulmonary artery smooth muscle cells (PASMCs) results in adverse vascular remodeling contributing to PAH. Understanding the mechanisms of PASMC proliferation may identify new targets for treatment. Chloride currents/channels (ICl) are expressed in PASMCs and their roles in proliferation have been suggested based on their importance in resting membrane potential and cell volume regulation. The present study explored the role of ICl in proliferation in rat and human PASMCs. We found that either nonspecific ICl inhibitors (DIDS or NPPB) or a putative specific blocker of swelling-activated ICl (ICl,swell) reduced proliferation of PASMCs cultured in serum-containing media. Patch-clamp studies showed that proliferating PASMCs had increased baseline ICl and ICl,swell in association with depolarized membrane potentials. Quantitative real-time RT-PCR studies identified expressions of CLC-3, a candidate gene of ICl,swell, and several other CLC genes in proliferating PASMCs. While selective knockdown of CLC-3 with lentiviral shRNA reduced PASMC proliferation, it had no effect on ICl,swell. These findings are consistent with the conclusion that ICl regulate proliferation of PASMCs and suggest that selective ICl inhibition may be useful in treating pulmonary arterial hypertension.

No description available.

Pulmonary arterial hypertension (PAH) is a rare but fatal disease with an annual mortality rate of 15% despite current therapies. Uncontrolled proliferation of pulmonary artery smooth muscle cells (PASMCs) results in adverse vascular remodeling contributing to PAH. Understanding the mechanisms of PASMC proliferation may identify new targets for treatment. Chloride currents/channels (ICl) are expressed in PASMCs and their roles in proliferation have been suggested based on their importance in resting membrane potential and cell volume regulation. The present study explored the role of ICl in proliferation in rat and human PASMCs. We found that either nonspecific ICl inhibitors (DIDS or NPPB) or a putative specific blocker of swelling-activated ICl (ICl,swell) reduced proliferation of PASMCs cultured in serum-containing media. Patch-clamp studies showed that proliferating PASMCs had increased baseline ICl and ICl,swell in association with depolarized membrane potentials. Quantitative real-time RT-PCR studies identified expressions of CLC-3, a candidate gene of ICl,swell, and several other CLC genes in proliferating PASMCs. While selective knockdown of CLC-3 with lentiviral shRNA reduced PASMC proliferation, it had no effect on ICl,swell. These findings are consistent with the conclusion that ICl regulate proliferation of PASMCs and suggest that selective ICl inhibition may be useful in treating pulmonary arterial hypertension.

Orientador: Fabíola Taufic Monica Iglesias / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-23T16:27:39Z (GMT). No. of bitstreams: 1 Faria_WagnerMendes_M.pdf: 1252281 bytes, checksum: ad80513967190699e0001046decc7731 (MD5) Previous issue date: 2013 / Resumo: Duas classes de medicamentos denominadas estimuladores e ativadores da guanilato ciclase solúvel (GCs) foram desenvolvidas para uso terapêutico em situações patológicas onde há menor formação ou biodisponibilidade NO ou tolerância farmacológica. A GCs é uma enzima heterodímera, composta pelas subunidades alfa (?) e beta (?), nas quais há a presença do grupo prostético heme e que catalisa a conversão da guanosina trifosfato (GTP) em guanosina monofosfato cíclico (GMPc) pela ação do NO. Em situações patológicas o átomo de ferro pode encontrar-se na sua forma oxidada (Fe3+), diminuindo assim a resposta máxima do óxido nítrico (NO). A principal diferença entre os moduladores da GCs é que os ativadores (BAY 58-2667, HMR 1766, BAY 60-2770) atuam de maneira mais eficaz mesmo quando a enzima encontra-se no estado oxidado. O objetivo do presente trabalho foi caracterizar funcionalmente o relaxamento induzido pelo BAY 60-2770 em artéria pulmonar isolada de coelho. O BAY 60-2770 (0,0001-100 ?M) relaxou de maneira potente (10,1 ± 0.04) e eficaz (105 ± 0,9 %) a artéria pulmonar, sendo este efeito significativamente potencializado na presença dos inibidores da GCs (ODQ, 10 ?M, 4,9 vezes), da fosfodiesterase tipo 5 (tadalafil, 100 ?M, 5,6 vezes) ou da sintase de óxido nítrico (LNAME, 100 ?M, 3,0 vezes). A presença do sequestrador de NO, do doador de NO, da indometacina, do bloqueador do canal de potássio ou a remoção endotelial não interferiram no relaxamento induzido pelo BAY 60-2770. A fenilefrina (0,00001-3 mM) e a estimulação elétrica (4-16 Hz) produziram contração dependente da concentração e frequência, respectivamente. Na presença de tetrodotoxina (TTX, 1 ?M) e fentolamina (1 ?M) houve abolição da resposta contrátil a estimulação elétrica, mostrando a liberação neurogênica de catecolamina. Na presença de BAY 60-2770 co-incubado com ODQ uma redução significativa na contração induzida pela estimulação elétrica foi observada. Apesar desta mesma redução ter sido observada na presença do L-NAME, a mesma não foi estatisticamente significante em comparação aos anéis incubados somente com BAY 60-2770 (1 ?M). Nossos resultados mostraram que a oxidação do grupamento heme, a inibição da fosfodiesterase e a ausência do NO favoreceram a resposta relaxante do BAY 60-2770 / Abstract: Soluble guanylate cyclase (sGC) stimulators and activators have been developed for use in pathophysiological condition when NO formation or bioavailability are impaired or when NO tolerance gas developed. Soluble guanylate cyclase is a heterodimer enzyme composed by alpha (?) and beta (?) subunits and a prostetic heme group. Soluble guanylate cyclase converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (GMPc) after nitric oxide (NO) activaton. Under pathophysiological conditions heme can be oxidized (Fe3+), thus reduzing NO efficacy. The main difference between stimulators and activators (BAY 58-2667, BAY 60-2770 and HMR 1766) is that the latter class of drugs is more efficacious when heme is oxidized. The aim of the present study is to characterize the relaxation induced by BAY 60-2770 in isolated pulmonary artery from rabbit. BAY 60-2770 (0.0001-100 ?M) produced concentration dependent relaxation with potency and maxima response values of 10,1 ± 0.04 and 105 ± 0.9%, respectively. The inhibition of sGC (ODQ, 10 ?M) or phosphodiesterase type 5 (tadalafil, 100 ?M) or the nitric oxide synthase (L-NAME, 100 ?M) produced significantly leftward shifts by, approximately, 4.9, 5.4 and 3.0, respectively. The NO-scavenger, the NO-donor, the cyclooxygenase inhibition, the potassium channel blocker or endothelial removal did not interfere on the pharmacological parameters of BAY 60-2770. Phenylephrine (PE, 0.0001- 3 mM) and electrical field stimulation (EFS, 4-16 Hz) induced concentration and frequency dependent-contraction, respectively. Phentolamine (1 ?M) and tetrodotoxin (TTX, 1 ??) practically abolished EFS-induced contraction, showing the neurogenic source of catecholamines. Co-treatment with BAY 60-2770 with ODQ reduced significantly the EFS-induced contraction in comparison with BAY 60- 2770 (1 ?M) alone. Although we have observed a tendency of reduction in the amplitude of contraction when BAY 60-2770 was co-incubated with L-NAME, it was not statistically significant. Therefore, our results showed that the oxidation of heme group, the inhibition of phosphodiesterase and lower levels of NO favoured the relaxing response of BAY 60- 2770 in isolated rabbit pulmonary artery / Mestrado / Farmacologia / Mestre em Farmacologia

L'hypertension artérielle pulmonaire (HTAP) est caractérisée par un intense remodelage de la microcirculation pulmonaire affectant principalement les artérioles pulmonaires musculaires. Lorsqu'elle survient en l'absence de condition associée, l'HTAP est considérée comme idiopathique (HTAPi). L'HTAP représente une pan-vasculopathie au cours de laquelle chaque type cellulaire (cellules endothéliale, musculaire lisse, fibroblaste) constituant la paroi vasculaire joue un rôle spécifique dans la réponse à l'agression. Les buts de ce travail étaient d'explorer l'implication de différentes voies de signalisation dans l'initiation ou la progression de la maladie. Les différentes études ont été réalisées à partir de cultures de cellules musculaires lisses (CML) d'artère pulmonaire et de cellules endothéliales (CE) pulmonaires obtenues à partir de prélèvements pulmonaires humains obtenus lors de transplantation chez des patients souffrant d'HTAP réfractaire.Des études antérieures avaient souligné le rôle majeur de la sérotonine au cours de l'HTAP idiopathique. Dans une première étude, nous avons étudié le rôle respectif de la sérotonine (5-HT), de son transporteur (5-HTT) ou de ses récepteurs (5-HT1B, 5-HT2A et 5-HT2B) dans le remodelage vasculaire pulmonaire mis en évidence dans l'HTP associée à diverses conditions. Les résultats de cette première étude montraient qu'une surexpression du 5-HTT dans les CML d'artère pulmonaire est une voie physiopathologique commune impliquée dans le remodelage vasculaire pulmonaire observé dans l'HTAP idiopathique, la maladie veino-occlusive et l'HTAP associée à différentes pathologies.Des mécanismes inflammatoires jouent probablement un rôle important dans la physiopathologie du remodelage microvasculaire pulmonaire. En effet, des infiltrats composés de cellules inflammatoires mononucléées (macrophages, lymphocytes T et B et cellules dendritiques) sont fréquemment mis en évidence autour des lésions vasculaires pulmonaires de patients présentant une HTAP idiopathique. Les mécanismes impliqués dans le recrutement de ces cellules mononucléées demeurent mal compris et nous avons étudié le rôle d'une chimiokine, CC chemokine ligand 2 (CCL2). Les résultats de cette seconde étude montraient que CCL2 était surexprimée au cours de l'HTAP idiopathique. La source de cette surexpression semblait provenir des cellules endothéliales pulmonaires. CCL2 agissait non seulement sur le recrutement des monocytes mais également sur les cellules musculaires lisses vasculaires pulmonaires en stimulant leur prolifération et leur migration.Des mutations germinales de gènes codant pour des membres de la famille des récepteurs du TGF tels que BMPR2 (Bone Morphogenic Protein Receptor type 2) sont retrouvées dans près de 70% des cas d'HTAP familiale mais également chez 10 à 30 % des cas d'HTAPi apparemment non familiales. Ces patients sont regroupés sous le terme d'HTAP « héritable » (HTAPh). Nous avons, dans une troisième étude, évalué si la dysfonction des voies de signalisation secondaires aux mutations de BMPR2 pouvait avoir des conséquences sur la voie de l'endothéline 1 (ET-1) qui représente l'une des cibles thérapeutiques de choix au cours de l'HTAP. Les résultats de cette troisième étude montraient que l'ET-1 était surexprimée au cours de l'HTAP avec ou sans mutation de BMPR2. En revanche, une surexpression des récepteurs ET-A dans les CML était mise en évidence au cours de l'HTAPh et était associée à une augmentation de l'effet pro-proliférant de l'ET-1 sur les CML.Ces résultats révèlent que des facteurs vaso-actifs (ET-1, 5-HT) et inflammatoires jouent un rôle déterminant dans la physiopathologie de l'HTAP et pourraient représenter de nouvelles cibles thérapeutiques. / Pulmonary arterial hypertension (PAH) is characterized by intense pulmonary vascular remodelling affecting mainly the muscular pulmonary arteries and leading to increased pulmonary vascular resistance. When it occurs in the absence of associated conditions, PAH is regarded as idiopathic (iPAH). PAH represents a panvasculopathy in which each cell type constituting the vascular wall (endothelial cells, smooth muscle cells, fibroblast) plays a specific role. The aims of this work were to explore the implication of various pathways in the initiation or the progression of the disease. The various studies were carried out using pulmonary artery smooth muscle cells (PASMC) and pulmonary endothelial cells (PEC) obtained during lung transplantation from patients with refractory PAH.Former studies have emphasized the major role of serotonin (5-HT) in the process of pulmonary vascular remodelling in iPAH. In a first study, we studied the respective role of 5-HT, the 5-HT transporter (5-HTT) and several 5-HT receptors (5-HT1B, 5-HT2A and 5-HT2B) on PASMC proliferation in cells from patients with PH associated with various conditions. The results of this first study showed that 5-HTT overexpression in PASMC is a common pathogenic mechanism in various forms of PH.Inflammatory cytokines may affect pulmonary vascular remodelling in iPAH. Indeed, iPAH frequently reveals inflammatory infiltrates corresponding to macrophages, lymphocytes and dendritic cells in the range of plexiform lesions as well as in other vascular lesions. The mechanisms underlying pulmonary vessel infiltration by monocytes / macrophages are unclear and the role for inflammatory cells in pulmonary vascular remodeling remains to be elucidated. This second study showed that iPAH is associated with an overexpression of CCL2. PEC are a major source of CCL2, which behaves as chemoattractant for circulating inflammatory cells and as growth factor for PASMC.Germline mutations of bone morphogenetic protein (BMP) receptor type 2 (BMPR-2), a member of the transforming growth factor (TGF)-β receptor family, have been reported in nearly 70% of patients with the heritable form of the disease (hPAH), and in 10–30% of patients with sporadic iPAH. In a third study, we evaluated the functional consequences of BMPR-2 mutations on the endothelin 1 (ET-1) pathway which represents one of the therapeutic targets on PAH. The results of this third study showed that iPAH and hPAH were associated with a similar overexpression of ET-1. In contrast, ETA receptor mRNA levels which were increased in PASMC from patients with iPAH and hPAH compared to controls were much higher in hPAH than in iPAH cells. Consequently, the growth promoting effect of ET1 on PASMC was higher in PASMC from patients with iPAH, and was markedly elevated in PASMC from patients with hPAH. No changes in ETB receptor mRNA levels could be detected in PASMC from patients with iPAH or hPAH in comparison with controls.These results reveal that vasoactive factors (ET-1, 5-HT) and inflammatory factors play a determining role in the pathophysiology of PAH and could represent new therapeutic targets.

Background: Pulmonary artery sarcoma is a rare tumor with a poor prognosis. Case Report: We report the case of a 64-year-old man with an intimal pulmonary artery sarcoma presenting with severe high oxygen flow-demanding dyspnea and weight loss of 12 kg in the last 6 months. On echocardiography, right heart insufficiency, markedly elevated right ventricular pressure, a pressure gradient along the right outflow tract, and a tumor mass adherent to the wall of the truncus pulmonalis were detected. The tentative diagnosis by echocardiographic findings was pulmonary artery sarcoma. Computed tomography of the thorax and 18-fluorodeoxyglucose positron emission tomography showed an advanced local tumor manifestation. Surgical resection of the tumor to improve hemodynamics confirmed the diagnosis. Conclusions: Pulmonary artery sarcoma should be considered as a rare differential diagnosis in patients with dyspnea due to right heart failure, particular in the case of additional weight loss, and echocardiographic examination is a useful first diagnostic approach in establishing the diagnosis. / Hintergrund: Das Pulmonalarteriensarkom ist eine seltene Erkrankung mit einer schlechten Prognose. Fallbericht: Wir berichten über einen 64-jährigen Mann mit einem intimalen Pulmonalarteriensarkom, der sich mit starker Luftnot trotz hoher Sauerstoffsubstitution und einem Gewichtsverlust von 12 kg in den letzten 6 Monaten vorstellte. Echokardiographisch fielen eine Rechtsherzinsuffizienz, ein deutlich erhöhter rechtsventrikulärer Druck, ein Druckgradient über dem rechten Ausflusstrakt und eine Tumormasse im Bereich des Trunkus pulmonalis mit Kontakt zur Gefäßwand auf. Die mittels Echokardiographie erhobene Verdachtsdiagnose lautete Pulmonalarteriensarkom. Die Computertomographie des Thorax und die 18-Flur-Desoxyglukose-Positron-Emissionstomographie erbrachten den Befund eines lokal fortgeschrittenen Tumors. Die chirurgische Resektion des Tumors, die zur Verbesserung der Hämodynamik durchgeführt wurde, bestätigte die Diagnose. Schlussfolgerungen: Das Pulmonalarteriensarkom sollte differenzialdiagnostisch als eine seltene Ursache der Luftnot im Rahmen einer Rechtsherzinsuffizienz, insbesondere bei zusätzlichem Gewichtsverlust, in Erwägung gezogen werden. Die Echokardiographie stellt eine wertvolle initiale Untersuchungsmethode bei der Diagnosestellung dar. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Indiana University-Purdue University Indianapolis (IUPUI) / 17-β estradiol (E2) exerts protective effects in hypoxia-induced pulmonary hypertension (HPH) via endothelial cell estrogen receptor (ER)-dependent mechanisms. However, the effects of hypoxia on ER expression in the pulmonary-right ventricle (RV) axis remain unknown. Based on previous data suggesting a role of ER-β in mediating E2 protection, we hypothesized that hypoxia selectively up-regulates ER-β in the lung and pulmonary endothelial cells. In our Male Sprague-Dawley rat model, chronic hypoxia exposure (10% FiO2) resulted in a robust HPH phenotype associated with significant increases in ER- β but not ER-α protein in the lung via western blotting. More importantly, this hypoxia-induced ER-β increase was not replicated in the RV, left ventricle (LV) or in the liver. Hence, hypoxia-induced ER-β up-regulation appears to be lung-specific. Ex vivo, hypoxia exposure time-dependently up-regulated ER-β but not ER-α in cultured primary rat pulmonary artery endothelial cells (RPAECs) exposed to hypoxia (1% O2) for 4, 24 or 72h. Furthermore, the hypoxia induced ER-β protein abundance, while not accompanied by increases in its own transcript, was associated with ER-β nuclear translocation, suggesting increase in activity as well as post-transcriptional up-regulation of ER-β. Indeed, the requirement for ER-β activation was indicated in hypoxic ER-βKO mice where administration of E2 failed to inhibit hypoxia-induced pro-proliferative ERK1/2 signaling. Interestingly, HIF-1α accumulation was noted in lung tissue of hypoxic ER-βKO mice; consistent with previously reported negative feedback of ER-β on HIF-1α protein and transcriptional activation. In RAPECs, HIF-1 stabilization and overexpression did not replicate the effects of ER- β up-regulation seen in gas hypoxia; suggestive that HIF-1α is not sufficient for ER-β up- regulation. Similarly, HIF-1 inhibition with chetomin did not result in ER-β down-regulation. HIF-1α knockdown in RPAECs in hypoxic conditions is currently being investigated. Hypoxia increases ER- β, but not ER-α in the lung and lung vascular cells. Interpreted in context of beneficial effects of E2 on hypoxic PA and RV remodeling, our data suggest a protective role for ER-β in HPH. The mechanisms by which hypoxia increases ER-β appears to be post-transcriptional and HIF-1α independent. Elucidating hypoxia-related ER-β signaling pathways in PAECs may reveal novel therapeutic targets in HPH.

Objetivo: Alterações do metabolismo energético tem sido identificadas em processos de hipertrofia miocárdica, sendo algumas consideradas benéficas, porém outras estão associadas a insuficiência cardíaca. O objetivo deste trabalho foi comparar a atividade de três enzimas do metabolismo energético em dois protocolos de sobrecarga sistólica do ventrículo direito (VD) num modelo experimental em cabritos. Métodos: 27 cabritos jovens foram divididos em três grupos: Sham (sem sobrecarga), Contínuo (sobrecarga sistólica constante) e Intermitente (4 períodos de 12 horas de sobrecarga sistólica, intercalados com 12 horas de descanso). Durante as 96 horas do protocolo, a sobrecarga sistólica foi ajustada a fim de atingir relação de pressão entre a aorta e o VD de 0,7. Medidas ecocardiográficas e hemodinâmicas foram realizadas antes e após o período de sobrecarga diariamente até o término do protoloco. Após o término do mesmo, os animais foram sacrificados a fim de obter dados morfológicos e a atividade máxima das enzimas Glicose 6 Fosfato Desidrogenase (G6PD), Hexoquinase (HK) e Lactato Desidrogenase (LDH). Resultados: Houve aumento de 92,1% e 46,5% nas massas do VD e septal no grupo Intermitente, respectivamente, quando comparado ao grupo Sham, enquanto que no grupo Contínuo houve incremento de 37,2% somente na massa septal. O VD e Septo dos grupos submetidos à sobrecarga sistólica contínua e intermitente do VD apresentaram um aumento discreto, porém significativo, do conteúdo de água (VD, p=0,0014; Septo, p=0,0004) em relação ao grupo Sham. Ao final do protocolo, foi observado um aumento significativo de 103,8% da espessura do VD no grupo Intermitente, comparado a um aumento de 38,4% do grupo Contínuo. Houve também dilatação ventricular significativa no grupo Contínuo ao longo do protocolo, quando comparado aos outros grupos (p<0,001). Piores índices de desempenho miocárdico ocorreram no grupo Contínuo no momentos 72 e 96 horas, quando comparados ao grupos Sham (P<0,039) e Intermitente (P<0,001). A razão da atividade máxima da G6PD do VD pelo VE revelou um aumento de 130,1% no grupo contínuo (p= 0,012) e de 39,8% no grupo Intermitente (p=0,764), quando comparados ao grupo Sham. O processo de hipertrofia aguda do VD não afetou a atividade enzimática da HK e LDH nos grupos estudados. Conclusões: Apesar de haver uma sobrecarga sistólica proporcionalmente menor no VD do grupo intermitente, a bandagem intermitente do TP promoveu maior hipertrofia do VD. A maior atividade da G6PD observada no grupo contínuo sugere maior produção de radicais livres via NADPH oxidase, haja vista que o ciclo das pentoses Fosfato incrementa a disponibilidade de NADPH citoplasmático, ocasionados pela maior demanda de um estímulo de sobrecarga miocárdica constante, um importante mecanismo de insuficiência cardíaca. Este estudo sugere que a preparação do ventrículo sub-pulmonar com a sobrecarga sistólica intermitente poderá proporcionar melhor resultado para a cirurgia de Jatene em dois estágios que a sobrecarga contínua / Objective: Altered energy metabolism has been identified in myocardial hypertrophy. Some processes are considered beneficial, whereas others are linked to heart failure. The purpose of this study was to compare the activity of three different energy metabolism enzymes in two different protocols of right ventricle (RV) systolic overload in young goats. Methods: 27 young goats were separated into three groups: Sham (no overload), Continuous (continuous systolic overload) and Intermittent (4 periods of 12-hour systolic overload, alternated with a 12-hour resting period). During a 96-hour protocol, systolic overload was adjusted to achieve a 0.7 RV / aortic pressure ratio. Echocardiographic and hemodynamic evaluations were performed before and after systolic overload every day postoperatively. After the study period, the animals were humanely killed for morphological and Glucose-6-phosphate dehydrogenase (G6PD), hexoquinase (HK) and lactate dehydrogenase (LDH) activity assessment. Results: There was a 92.1% and 46.5% increase in RV and septal masses of Intermittent group, respectively, as compared to Sham group, while Continuous systolic overload resulted in 37.2% increase of only septal mass. There was a small, but significant increase in water content in RV and septum of Intermittent and Continuous groups, as compared to Sham group (RV, p=0.0014; Septum, p=0.0004). At the end of protocol, it was observed a greater increase in RV thickness (103.8%) in Intermittent group, as compared to Continous group (38.4%). There was also a significant right ventricle dilatation in Continuos group along the protocol, as compared to the other groups (p<0.001). A worsening RV myocardial performance index occurred in the continuous group at 72 hours and 96 hours, compared with the sham (P<0.039) and intermittent groups (P<0.001). Compared to Sham, RV to LV G6PD activity ratio was elevated by 130.1% in Continuous group (p= 0,012) and by 39.8% in Intermittent group (p=0.764). The acute hypertrophic process in the RV did not altered the HK and LDH enzymatic activity among study groups. Conclusions: Despite of a proportional lesser exposure to systolic overload, intermittent pulmonary trunk banding promoted greater RV hypertrophy. This study indicates that continuous systolic overload for ventricle retraining causes upregulation and hyperactivity of myocardial G6PD. Since pentose phosphate pathway enhances cytosolic NADPH availability, this altered energy substrate metabolism can elevate levels of free radicals by NADPH oxidase, an important mechanism in the pathophysiology of heart failure. It suggests that Intermittent systolic overload may provide better results for 2-stage Jatene operation as compared to continuous protocol